Business Description
Abivax SA
ISIN : FR0012333284
Compare
Compare
Traded in other countries / regions
ABVX.FranceABVX.USA2X1.Germany0RA9.UK IPO Date
2015-06-26Description
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.71 | |||||
| Equity-to-Asset | 0.6 | |||||
| Debt-to-Equity | 0.28 | |||||
| Debt-to-EBITDA | -0.42 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -5.3 | |||||
| 3-Year EPS without NRI Growth Rate | -6.5 | |||||
| 3-Year FCF Growth Rate | -1.8 | |||||
| 3-Year Book Growth Rate | 35.5 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 17.8 | |||||
| 9-Day RSI | 25.91 | |||||
| 14-Day RSI | 29.99 | |||||
| 3-1 Month Momentum % | -10.91 | |||||
| 6-1 Month Momentum % | -25.85 | |||||
| 12-1 Month Momentum % | -0.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.08 | |||||
| Quick Ratio | 4.08 | |||||
| Cash Ratio | 3.73 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -63.8 | |||||
| Shareholder Yield % | -78.38 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -156.24 | |||||
| ROA % | -77.26 | |||||
| ROIC % | -229.33 | |||||
| 3-Year ROIIC % | -379.46 | |||||
| ROC (Joel Greenblatt) % | -15040.88 | |||||
| ROCE % | -94.46 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.29 | |||||
| Price-to-Tangible-Book | 2.63 | |||||
| EV-to-EBIT | -1.84 | |||||
| EV-to-Forward-EBIT | -2.86 | |||||
| EV-to-EBITDA | -1.85 | |||||
| EV-to-Forward-EBITDA | -2.9 | |||||
| EV-to-Forward-Revenue | 333.63 | |||||
| EV-to-FCF | -2.53 | |||||
| Price-to-Net-Current-Asset-Value | 2.9 | |||||
| Price-to-Net-Cash | 3.45 | |||||
| Earnings Yield (Greenblatt) % | -54.35 | |||||
| FCF Yield % | -21.54 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Abivax SA Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -3.271 | ||
| Beta | 1.36 | ||
| 3-Year Sharpe Ratio | -0.11 | ||
| 3-Year Sortino Ratio | -0.21 | ||
| Volatility % | 40.62 | ||
| 14-Day RSI | 29.99 | ||
| 14-Day ATR (€) | 0.372585 | ||
| 20-Day SMA (€) | 7.98 | ||
| 12-1 Month Momentum % | -0.73 | ||
| 52-Week Range (€) | 7.11 - 15.42 | ||
| Shares Outstanding (Mil) | 63.34 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Abivax SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Abivax SA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Abivax SA Frequently Asked Questions
What is Abivax SA(XPAR:ABVX)'s stock price today?
The current price of XPAR:ABVX is €7.14. The 52 week high of XPAR:ABVX is €15.42 and 52 week low is €7.11.
When is next earnings date of Abivax SA(XPAR:ABVX)?
The next earnings date of Abivax SA(XPAR:ABVX) is 2025-04-02 Est..
Does Abivax SA(XPAR:ABVX) pay dividends? If so, how much?
Abivax SA(XPAR:ABVX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers